Publications
457
Citations
17,561
Est. group size
~54
Recurring co-author estimate
Active years
26
Publishing since 2001
Typically publishes in teams of ~19 · 1% small-team papers (≤3 authors) · across 43 venues
- Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial
European Urology · 2026
- SWOG S1602: A phase III randomized trial to evaluate BCG strain differences and priming with intradermal BCG before intravesical therapy for BCG-naïve high-grade non-muscle invasive bladder cancer (NCT #03091660).
Journal of Clinical Oncology · 2026
- Real-World effectiveness of second-line cabozantinib in metastatic renal cell carcinoma in the era of immunotherapy combinations: Results from the international metastatic renal cell carcinoma database consortium (IMDC)
Kidney Cancer · 2026
- Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes
Clinical Genitourinary Cancer · 2025
- Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617
The Oncologist · 2025
- Real-world outcomes of first-line dual immunotherapy versus combination VEGF immunotherapy in intermediate-poor risk metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Data Consortium (IMDC).
Journal of Clinical Oncology · 2025
- Cabozantinib real-world effectiveness in the second-line setting of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
Journal of Clinical Oncology · 2025
- Real-world quality of life (QOL) for patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy (ST) in the prospective observational ODYSSEY study.
Journal of Clinical Oncology · 2025
- Real-world quality of life (QOL) in patients (pts) with metastatic renal cell carcinoma (mRCC) on active surveillance (AS) in the ODYSSEY prospective observational study.
Journal of Clinical Oncology · 2025
- Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
New England Journal of Medicine · 2024
- Final Overall Survival Analysis of S1500: A Randomized, Phase II Study Comparing Sunitinib With Cabozantinib, Crizotinib, and Savolitinib in Advanced Papillary Renal Cell Carcinoma
Journal of Clinical Oncology · 2024
- First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study
European Urology · 2024
- Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1
JCO Precision Oncology · 2024
- Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaboration
Prostate Cancer and Prostatic Diseases · 2024
- Association of Tumor Mutational Burden and Microsatellite Instability With Response and Outcomes in Patients With Urothelial Carcinoma Treated With Immune Checkpoint Inhibitor
Clinical Genitourinary Cancer · 2024
- Journal of Clinical Oncology×124
- European Urology×14
- Annals of Oncology×13
- The Journal of Urology×12
- Clinical Genitourinary Cancer×12
- Amir Mortazavi
Medicine · The Ohio State University
- Irene Tsung
Medicine · University of Michigan
- Phillip L. Palmbos
Medicine · University of Michigan
- Shang-Jui Wang
Medicine · The Ohio State University
- Debasish Sundi
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 25, 2026.
Claim or correct this profile